Comparison · NCT01844518-55124a91
SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: Number of Participants With Positive Immunogenicity Response in the Cumulative Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SC Abatacept Ages 6 to 17 vs SC Abatacept Ages 2 to 5: Number of Participants With Positive Immunogenicity Response in the Cumulative Period. Trial comparisons, record NCT01844518-55124a91. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01844518-55124a91
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0465 | 0.0238 | 0.0891 | wilson | |
| Risk in group 2 | 0.152 | 0.0757 | 0.282 | wilson | |
| Risk difference, group 1 minus group 2 | -0.106 | -0.238 | -0.0182 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.306 | 0.117 | 0.799 | log | |
| Odds ratio, group 1 over group 2 | 0.272 | 0.093 | 0.795 | log | |
| Number needed to treat, for one fewer participant with the outcome on SC Abatacept Ages 6 to 17 than on SC Abatacept Ages 2 to 5 | 9.46 | 4.21 | 55.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SC Abatacept Ages 6 to 17 | Subcutaneous (SC) abatacept administered by prefilled syringe (PFS) once weekly according to the following weight-tiered dosing regimen: 10 to less than (\<) 25 kilogram (kg) (50 milligram \[mg\] in 0.4 milliliter \[mL\] PFS), 25 to \< 50 kg (87.5 mg in 0.7 mL PFS) and 50 kg (125 mg in 1 mL PFS). | 8 | 172 | OG000 |
| Group 2 | SC Abatacept Ages 2 to 5 | SC abatacept administered by PFS once weekly according to the following weight-tiered dosing regimen: 10 to \< 25 kg (50 mg in 0.4 mL PFS), 25 to \< 50 kg (87.5 mg in 0.7 mL PFS) and 50 kg (125 mg in 1 mL PFS). | 7 | 46 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Positive Immunogenicity Response in the Cumulative Period
- Description
Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose regardless of whether they discontinued early in the short term (ST) or long term (LT) period, elected not to enter the LT period, or completed both ST and LT periods.
- Time frame
- From first dose up to 6 months following treatment discontinuation (up to approximately 2 years)
- Population
- All treated participants in the cumulative period with available immunogenicity measurements.
Source ClinicalTrials.gov
Trial
- Title
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
- NCT number
- NCT01844518
- Phases
- PHASE3
- Conditions
- Active Polyarticular Juvenile Idiopathic Arthritis
- Interventions
- Abatacept
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2016-03-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01844518?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01844518-55124a91